Title : Efficacy of the nanoparticle-drug conjugate CRLX101 in combination with bevacizumab in metastatic renal cell carcinoma: results of an investigator-initiated phase I-IIa clinical trial.

Pub. Date : 2016 Aug

PMID : 27457310






1 Functional Relationships(s)
Download
Sentence
Compound Name
Protein Name
Organism
1 CRLX101 is an investigational camptothecin-containing nanoparticle-drug conjugate (NDC), which durably inhibits HIF1alpha and HIF2alpha in preclinical models and in gastric cancer patients. Camptothecin hypoxia inducible factor 1 subunit alpha Homo sapiens